GLP-1

Plug & Play, the innovation platform, is turning its attention to nutrition products designed to accompany GLP-1 weight-loss drugs, calling it the next frontier for the microbiome sector. The idea is to support people on medications like Ozempic with tailored nutrition that addresses side effects and nutrient gaps. The move reflects growing interest among food and supplement companies in serving the fast-expanding population using GLP-1 treatments.

Hershey CEO Kirk Tanner sits down with Fast Company to discuss how the chocolate giant is adapting to consumers using GLP-1 weight-loss drugs, integrating artificial intelligence into its operations, and working to keep a century-old confectionery brand culturally relevant. The interview touches on shifting snacking habits, health trends pressuring candy sales, and how a legacy company balances tradition with technological change.

New research indicates that close to one in six children taking GLP-1 weight-loss and diabetes medications develop nutritional deficiencies. The finding raises concerns about the dietary impact of these increasingly prescribed drugs in pediatric care, with experts urging monitoring of vitamins and minerals in young patients on long-term treatment.

A randomized, double-blind, placebo-controlled trial published in Nature tested safiglipron, an oral small-molecule GLP-1 receptor agonist, in people with early type 2 diabetes. Unlike injectable GLP-1 drugs such as semaglutide, safiglipron is taken as a pill, which could make treatment easier to access. The publication is drawing attention as drugmakers race to develop oral alternatives to popular injectable weight and diabetes medications.

A health news roundup covers four topics: cychlorphine, a substance drawing attention for potential effects on testosterone levels; possible links between GLP-1 weight-loss and diabetes drugs and vision loss; and an ongoing salmonella outbreak tied to jalapeño peppers. Together the items touch on medication safety, supplement trends and a foodborne illness investigation that health officials are monitoring.

Supplement company Smidge has introduced a GLP-1 companion bundle aimed at supporting digestion and nutrient intake for people taking GLP-1 medications, which are known to affect appetite and gut function. The bundle is positioned as a nutritional support product for users of these weight-loss and diabetes drugs.

Drugs in the GLP-1 class, such as Ozempic and Wegovy, are being described as changing more than obesity treatment, with new discussion of their effects on mental health. The Atlantic examines how these medications may influence mood, addiction and behavior, suggesting the story of weight loss medicine is expanding into psychiatry and brain science.

Supplement brand Smidge has introduced a nutrition bundle combining five supplements into a single daily routine, aimed at people taking GLP-1 weight-loss medications. The concept targets nutritional gaps reported by users of drugs like Ozempic and Wegovy, who often eat less and may miss key nutrients. It reflects a broader wave of products being marketed to the fast-growing GLP-1 user base.

A new wave of obesity medicines is being discussed as the field looks beyond the established GLP-1 drugs semaglutide and tirzepatide. Coverage highlights emerging treatments in development that could expand options for patients and clinicians treating obesity, a category that has drawn enormous attention since GLP-1 therapies reshaped weight-loss care. Details on specific drug candidates remain limited.